The Safety Profile of Nonprescription Ibuprofen in Multiple‐Dose Use: A Meta‐Analysis
The DOI matches its Crossref record.
Abstract
A meta‐analysis was performed to compare the incidence of adverse experiences (AEs) during the multiple‐dose use of nonprescription ibuprofen to a placebo. Eight studies, with doses ranging from 800 to 1200 mg/day and durations of 1 to 10 days, met the criteria for inclusion. AEs were classified according to COSTART, except that “abdominal pain” was conservatively reassigned to the digestive system. In each study, the overall AE frequency among ibuprofen‐treated subjects (n = 1094) was numerically less than or equal to the placebo (n = 1093). Pooled across all studies, placebo subjects reported AEs significantly (p = 0.018) more often (31.7%) than ibuprofen subjects (27.4%). The frequency of digestive system AEs was comparable (p = 0.420) for the placebo (11.0%) and ibuprofen (12.1%); there was no significant difference for any specific digestive system AE. AE frequency in the “body‐as‐a‐ whole” category was significantly higher (p < 0.001) in the placebo (20.4%) than in ibuprofen (14.8%). The number of severe AEs in all of these categories was lower for ibuprofen than for the placebo. These data indicate that nonprescription ibuprofen has an excellent side effect profile in multiple‐dose use, with a frequency of gastrointestinal AEs comparable to a placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ibuprofen: pharmacology, efficacy and safety
Rainsford, K. D. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0016-x · Cited by 667
Ong, C. K. S., Seymour, R. A., Lirk, P., & Merry, A. F. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181cf9281 · Cited by 631
Nonsteroidal anti-inflammatory drugs and opioids in postsurgical dental pain
Hersh, E. V., Moore, P. A., Grosser, T., Polomano, R. C., Farrar, J. T., Saraghi, M., Juska, S. A., Mitchell, C. H., & Theken, K. N. (2020) · Journal of Dental Research · doi:10.1177/0022034520914254 · Cited by 106
“…data reveal that short-term use of NSAIDs (10 d or less), especially in the OTC dosage range, is usually very well tolerated with patient-reported side effect profiles no different from placebo (Kellstein et al. 1999; Bansal et al. 2001), the same cannot be said for drugs containing opioids.”
BackgroundCardiorenal Safety of OTC Analgesics
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417751070 · Cited by 31
“7%]).(58) Patients With Hypertension Furey and coworkers(59) investigated the renal effects of ibuprofen 400 mg 3 times a day compared with APAP 650 mg 3 times a day and ASA 650 mg 3 times a day for 7 days in a randomized, double-blind study of 25 patients aged 60 years with hydrochlorothiazide-treated stage 1 hyperte…”
Background
Metadata
- Authors
- Kellstein, D. E., Waksman, J. A., Furey, S. A., Binstok, G., & Cooper, S. A.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-05
- Volume
- 39
- Issue
- 5
- Pages
- 520-532
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1880393460
- Cited by
- 60
- References
- 0
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Safety Profile of Nonprescription Ibuprofen in Multiple‐Dose Use: A Meta‐Analysis. https://app.cochat.ai/papers/10.1177/009127009903900513
- The paper
- Kellstein, D. E., Waksman, J. A., Furey, S. A., Binstok, G., & Cooper, S. A. (1999). The Safety Profile of Nonprescription Ibuprofen in Multiple‐Dose Use: A Meta‐Analysis. The Journal of Clinical Pharmacology. https://doi.org/10.1177/009127009903900513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.